Your browser doesn't support javascript.
loading
Apolipoprotein-A is a potential prognostic biomarker for severe aplastic anemia patients treated with ATG-based immunosuppressive therapy: a single-center retrospective study.
Liu, Qi; Dong, Huijie; Li, Yuzhu; Shen, Yingying; Hong, Yilei; Chen, Ying; Liu, Shan; Wu, Xiaolian; Liu, Wenbin; Hu, Huijin; Zhao, Yuechao; Lin, Shenyun; Shen, Yiping; Zhou, Yuhong; Ye, Baodong; Wu, Dijiong.
Afiliação
  • Liu Q; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Dong H; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Li Y; Department of Respiratory Medicine, Haining Traditional Chinese Medical Hospital of Zhejiang Province, Haining, Zhejiang, China.
  • Shen Y; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Hong Y; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Chen Y; Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005), Zhejiang, People's Republic of China.
  • Liu S; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Wu X; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Liu W; Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005), Zhejiang, People's Republic of China.
  • Hu H; Department of Clinical Evaluation Center, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Zhao Y; Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005), Zhejiang, People's Republic of China.
  • Lin S; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Shen Y; Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005), Zhejiang, People's Republic of China.
  • Zhou Y; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Ye B; Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005), Zhejiang, People's Republic of China.
  • Wu D; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Lipids Health Dis ; 21(1): 93, 2022 Oct 04.
Article em En | MEDLINE | ID: mdl-36192750
ABSTRACT

BACKGROUND:

Anti-thymoglobulin (ATG)-based immunosuppressive treatment (IST) is the standard first-line management for patients with severe AA/very severe AA (SAA/VSAA) and is not suitable for allogeneic stem cell transplantation. The response predictor was not fully investigated.

OBJECTIVE:

The present study attempted to explore other characteristics, such as serum lipid changes, during ATG-based IST and analyzed their significance in predicting IST response and survival.

METHODS:

A total of 61 newly diagnosed SAA/VSAA patients who received ATG-based IST were enrolled from January 2011 to June 2019. The blood lipid levels, immunoglobulins, and peripheral T lymphocytes were retrospectively collected, and their correlations with IST response, estimated 8.5-year overall survival (OS) and event-free survival (EFS) were analyzed.

RESULTS:

The overall response (OR)/complete remission (CR) at 3, 6, and 9 months was 24.6%/6.6%, 52.5%/14.8%, and 65.6%/23.0%, respectively. Based on the 9-month response effect, patients were divided into IST-response (IST-R) and IST-nonresponse (IST-NR) groups. The subgroup baseline characteristics showed that the disease severity grade, absolute neutrophil granulocyte count (ANC), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and apolipoprotein-A (Apo-A) differed between the IST-R and IST-NR groups. Patients with lower Apo-A (< 1.205 g/L) level pretreatment had a better event-free survival (EFS), and a moderate negative correlation was established between the pretreatment Apo-A and 9-month response (P = 0.004). In addition, the T-cell subset and immunoglobulin analyses showed that the responsive patients had a low serum IgA level, which decreased further after therapy. Additionally, a moderate negative correlation was established between the 3-month IgA and 9-month response (P = 0.006).

CONCLUSION:

Serum Apo-A is a prognostic biomarker for newly diagnosed < 60-year-old SAA/VSAA patients who received ATG-based IST (registered at chictr.org.cn as # ChiCTR2100052979).
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anemia Aplástica Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans / Middle aged Idioma: En Revista: Lipids Health Dis Assunto da revista: BIOQUIMICA / METABOLISMO Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anemia Aplástica Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans / Middle aged Idioma: En Revista: Lipids Health Dis Assunto da revista: BIOQUIMICA / METABOLISMO Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China